The first-in-class YAP/TEAD inhibitor VT3989 was well tolerated with durable antitumor responses in patients with advanced malignant mesothelioma and other tumors with NF2 mutations, according to results of a phase I trial led by researchers at MD Anderson Cancer Center. The first-in-human study was presented today at the 2023 American Association for Cancer Research annual meeting.
The CD70-targeting allogeneic CAR T-cell therapy, ALLO-316, demonstrated encouraging response rates and disease control rates in patients with metastatic clear cell renal cell carcinoma, according to results of a phase I trial led by researchers at MD Anderson Cancer Center and presented at the American Association for Cancer Research annual meeting.
A large retrospective study conducted by physician researchers from Roswell Park Comprehensive Cancer Center shows benefits of chemotherapy for many patients with early-stage breast cancer with rare variant histology, or tumor anatomy. These findings were presented by first author Arya Mariam Roy during the American Association for Cancer Research annual meeting.
MD Anderson Cancer Center researchers have identified recent developments in effective combination therapies for patients with BRAF V600E mutations, an approach to identify cancer biomarkers in extracellular vesicles, therapeutic strategies for improving treatment responses in non-small cell lung cancer, and a novel combination therapy to overcome treatment resistance in a subset of patients with acute myeloid leukemia.
A new approach to chimeric antigen receptor T-cell therapy has shown great promise against small cell lung cancer in a preclinical study. The findings cover new ground in our understanding of how CAR T can be employed against solid-tumor cancers, and provide support for further studies in cancer patients.
A University of Rochester/Wilmot Cancer Institute team discovered the molecule responsible for guiding T cells toward tumors.
A phase II clinical trial led by Winship Cancer Institute of Emory University showed a combination of Keytruda (pembrolizumab) and Cabometyx (cabozantinib, also known as Cometriq) was well tolerated and benefitted 91% of participating patients with recurrent/metastatic head and neck squamous cell carcinoma.
Black and Hispanic older adults whose annual income is slightly above the federal poverty level are more likely than their white peers to face cost-related barriers to accessing health care and filling medications for chronic conditions, according to new research led by a University of Pittsburgh School of Public Health scientist.
Research led by scientists at UCLA Jonsson Comprehensive Cancer Center found that responses to PD-1 checkpoint blockade immunotherapy in patients with advanced melanoma depended on whether or not they had previously received another immunotherapy—CTLA-4 blockade—as well as other factors.
Researchers from New Century Health and Neighborhood Health Plan of Rhode Island presented findings from their efforts to increase adoption of hypofractionation in breast cancer patients at the National Comprehensive Cancer Care Network conference, on March 31.
